Literature DB >> 9445041

Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.

L Mortara1, F Letourneur, H Gras-Masse, A Venet, J G Guillet, I Bourgault-Villada.   

Abstract

In this report, we assessed the evolution of the cytotoxic T-lymphocyte (CTL) response induced by an epitope vaccine. In two macaques immunized with a mixture of lipopeptides derived from simian immunodeficiency virus (SIV) Nef and Gag proteins, CTL responses were directed against the same, single epitope of the Nef protein (amino acids 128 to 137) presenting an alanine at position 136 (Nef 128-137/136A). However, after 5 months of SIV infection, peripheral blood mononuclear cells from both macaques lost their ability to be stimulated by autologous SIV-infected cells while still retaining their capacity to generate cytotoxic responses after specific Nef 128-137/136A peptide stimulation. The sequences of the pathogenic viral isolate used for the challenge showed a mixture of several variants. Within the Nef epitopic sequence from amino acids 128 to 137, 82% of viral variants expressed the epitopic peptide Nef 128-137/136A; the remaining variants presented a threonine at position 136 (Nef 128-137/136T). In contrast, sequence analysis of cloned proviral DNA obtained from both macaques 5 months after SIV challenge showed a different pattern of quasi-species variants; 100% of clones presented a threonine at position 136 (Nef 128-137/136T), suggesting the disappearance of viral variants with an alanine at this position under antiviral pressure exerted by Nef 128-137/136A-specific CTLs. In addition, 12 months after SIV challenge, six of eight clones from one macaque presented a glutamic acid at position 131 (Nef 128-137/131E+136T), which was not found in the infecting isolate. Furthermore, CTLs generated very early after SIV challenge were able to lyse cells sensitized with the Nef 128-137/136A epitope. In contrast, lysis was significantly less effective or even did not occur when either the selected peptide Nef 128-137/136T or the escape variant peptide Nef 128-137/131E+136T was used in a target cell sensitization assay. Dose analysis of peptides used to sensitize target cells as well as a major histocompatibility complex (MHC)-peptide stability assay suggested that the selected peptide Nef 128-137/136T has an altered capacity to bind to the MHC. These data suggest that CTL pressure leads to the selection of viral variants and to the emergence of escape mutants and supports the fact that immunization should elicit broad CTL responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445041      PMCID: PMC124619     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells.

Authors:  D Moskophidis; F Lechner; H Pircher; R M Zinkernagel
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

2.  Peripheral clonal deletion of antiviral memory CD8+ T cells.

Authors:  D Moskophidis; E Laine; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1993-12       Impact factor: 5.532

3.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells.

Authors:  J Sloan-Lancaster; B D Evavold; P M Allen
Journal:  Nature       Date:  1993-05-13       Impact factor: 49.962

5.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers.

Authors:  R Cheynier; P Langlade-Demoyen; M R Marescot; S Blanche; G Blondin; S Wain-Hobson; C Griscelli; E Vilmer; F Plata
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

6.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Authors:  S L Rowland-Jones; D F Nixon; M C Aldhous; F Gotch; K Ariyoshi; N Hallam; J S Kroll; K Froebel; A McMichael
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

7.  Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes.

Authors:  L C Eisenlohr; J W Yewdell; J R Bennink
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

8.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells.

Authors:  S C Jameson; F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

9.  Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes.

Authors:  N L Lill; M J Tevethia; W G Hendrickson; S S Tevethia
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

10.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.

Authors:  A Carmichael; X Jin; P Sissons; L Borysiewicz
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  24 in total

1.  Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses.

Authors:  R Kaul; S L Rowland-Jones; J Kimani; T Dong; H B Yang; P Kiama; T Rostron; E Njagi; J J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts.

Authors:  Thomas C Friedrich; Adrian B McDermott; Matthew R Reynolds; Shari Piaskowski; Sarah Fuenger; Ivna P De Souza; Richard Rudersdorf; Candice Cullen; Levi J Yant; Lara Vojnov; Jason Stephany; Sarah Martin; David H O'Connor; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response.

Authors:  Thomas C Friedrich; Christopher A Frye; Levi J Yant; David H O'Connor; Nancy A Kriewaldt; Meghan Benson; Lara Vojnov; Elizabeth J Dodds; Candice Cullen; Richard Rudersdorf; Austin L Hughes; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

5.  Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Authors:  Sharon E Frey; Laurence Peiperl; M Juliana McElrath; Spyros Kalams; Paul A Goepfert; Michael C Keefer; Lindsey R Baden; Michelle A Lally; Kenneth Mayer; William A Blattner; Clayton D Harro; Scott M Hammer; Geoffrey J Gorse; John Hural; Georgia D Tomaras; Yves Levy; Peter Gilbert; Allan deCamp; Nina D Russell; Marnie Elizaga; Mary Allen; Lawrence Corey
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

6.  Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.

Authors:  H Gahéry-Ségard; G Pialoux; B Charmeteau; S Sermet; H Poncelet; M Raux; A Tartar; J P Lévy; H Gras-Masse; J G Guillet
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Peripheral blood mononuclear cells of HIV-infected patients contain CD8 T cells that form conjugates with and kill HIV-infected autologous CD4 T cells.

Authors:  Ehud Chorin; Orit Gal-Garber; Yael Yagel; Dan Turner; Boaz Avidor; Gideon Berke; David Hassin
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

8.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques.

Authors:  Shanmugalakshmi Sadagopal; Rama Rao Amara; Sunil Kannanganat; Sunita Sharma; Lakshmi Chennareddi; Harriet L Robinson
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.